Sort   by:  
 Page size 
GenomicsSingle cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
Single cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
PRJNA687070 | ENA
GenomicsSingle cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
Single cell DNA sequencing reveals complex mechanisms of resistance to quizartinib
PRJNA687071 | ENA
ProteomicsTranslatome proteomics of primary human FLT3-ITD+ AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
Primary human AML cells (newly diagnosed, prior to treatment initation) was obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. Cells were treated ex vivo with DMSO vehicle control or 10 nM FLT3 inhibitors quizartinib, crenolanib, gilteritinib for 6 hour...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD034081 | Pride
Aml Gilteritinib Flt3 Translatome Quizartinib Crenolanib 
UnknownQuizartinib (AC220): a promising option for acute myeloid leukemia.
Not available
S-EPMC6497874 | biostudies-literature
UnknownEffect of Food on the Pharmacokinetics of Quizartinib.
Not available
S-EPMC7027461 | biostudies-literature
ProteomicsGlobal phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
Treatment with inhibitors of the receptor tyrosine kinase FLT3 are currently studied as promising therapies in acute myeloid leukemia (AML). However, only a subset of patients benefit from these treatments and the presence of activating mutations within FLT3 can predict response to a certain extent ...
ORGANISM(S): Homo sapiens (Human) 
2017-05-10 | PXD006475 | Pride
Biomarker  classification  aml  ac220  quizartinib  phosphoproteomics  response prediction 
UnknownConcentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia.
Not available
S-EPMC7946665 | biostudies-literature
UnknownDasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.
Not available
S-EPMC7606260 | biostudies-literature
UnknownCrystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).
Not available
S-EPMC4383440 | biostudies-literature
UnknownPopulation Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.
Not available
S-EPMC7689835 | biostudies-literature
Sort   by:  
 Page size